Scientific deep-dive
Do GLP-1s Cost More Muscle Than Dieting? What the Comparisons Show
GLP-1s likely cost more lean mass in kilograms because they remove more weight, but reviews disagree on whether the share of weight lost is higher than with dieting. Few trials compare them directly, and exercise appears to lower the lean share of weight lost.
Probably more in kilograms, because GLP-1s remove more weight, but whether they cost a larger share of the weight lost is unresolved, because the reviews disagree. One 20-trial meta-analysis put lean mass at 25.4% to 35.2% of weight lost on incretin drugs and 26.2% with lifestyle programs, calling them comparable (p = 0.42).[1] Another, limited to weight loss of at least 10%, reported 33.3% for incretins, 22.3% for diet without exercise and 7.7% for diet with exercise, with no formal statistical test across them.[2] Almost all of this compares different trials, so these are numerically larger or smaller figures, not proven differences.
Why two 2026 meta-analyses reach different answers
Eisa and Barood pooled 20 randomized trials with 15,782 participants measured by DXA or MRI. Semaglutide came in at 35.2% (95% CI 31.5 to 38.9), tirzepatide at 25.4% (22.8 to 28.0), liraglutide at 26.8% (23.1 to 30.5) and lifestyle at 26.2% (24.1 to 28.3).[1] The abstract gives a single p value for the comparison, not a drug-by-drug test, and semaglutide’s interval sits above lifestyle’s, so “comparable” is less secure for that drug. Heterogeneity was moderate (I² = 68%).[1]
Busk-Cirera and colleagues set a higher bar: randomized trials from 2015 onward that reached at least 10% weight loss. That left 12 diet and exercise, five incretin and four surgical studies, 1,334 participants in all. Fat-free mass made up 14.9% of weight lost with diet with or without exercise, 33.3% with incretins and 34.2% with surgery.[2] The authors concluded that diet and exercise produced the smallest reductions, yet their full text says “a direct statistical comparison across interventions was not performed,” so those shares are descriptive. Heterogeneity in the diet and exercise analysis was 95.7%, and some exercise arms gained fat-free mass.[2] One author holds Novo Nordisk stock and another reports Novo Nordisk grants and fees.[2]
Their kilogram figures also need care. The review lists -1.8 kg for diet and exercise, -4.8 kg for incretins and -9.1 kg for surgery, but the incretin number is a difference from placebo while the other two are pooled changes in study arms.[2] They were not built to be subtracted from each other.
| Source | Design | GLP-1 or incretin | Diet or lifestyle | Main caveat |
|---|---|---|---|---|
| Eisa 2026 | Meta-analysis, 20 RCTs | 25.4% to 35.2% by drug | 26.2%; 17.5% with resistance training | Across trials; I² 68% |
| Busk-Cirera 2026 | Meta-analysis, at least 10% weight loss | 33.3% | 22.3% diet only; 7.7% diet plus exercise | No statistical test between groups |
| Batsis 2026 | Systematic review, 35 studies | Median 28.3% (IQR 15.9% to 39.9%) | Comparators lost a median of 2.5% of weight | No meta-analysis possible |
| Look 2025 (SURMOUNT-1) | DXA substudy, 72 weeks | About 25% (pooled doses; weight -21.3%) | About 25% (placebo plus lifestyle; weight -5.3%) | Post hoc share; only 36 placebo participants; manufacturer authored |
What the same-trial comparisons show
Few studies put the two approaches side by side. One 2026 review found that only two comparative studies informed its primary muscle-quantity analysis, and it rated the evidence low to very low certainty, too imprecise to support or rule out preferential fat loss.[4]
One direct randomized test is small and favors dieting. In 88 adults with obesity and prediabetes, 14 weeks of calorie restriction (-390 kcal/day) was compared with liraglutide 1.8 mg daily and sitagliptin. Lean mass fell significantly within the liraglutide group (p = 0.007) and not within the calorie-restriction group, though the between-group difference in lean mass was not significant. The fat-to-lean ratio fell 6.5% with restriction and 2.2% with liraglutide (p = 0.02 across the three arms).[5] The diet group also lost more weight, the dose was modest and semaglutide and tirzepatide were not tested, so this one trial can’t settle the question for the drugs most people now use.[5]
The SURMOUNT-1 DXA substudy points the other way. At week 72, tirzepatide (pooled doses, n = 124) reduced weight by 21.3%, fat mass by 33.9% and lean mass by 10.9%, compared with 5.3%, 8.2% and 2.6% on placebo (n = 36), and, in a post hoc analysis, about 25% of weight lost was lean mass in both groups.[6] Placebo participants also received lifestyle counseling aimed at a 500 kcal daily deficit, so this is the closest thing to a same-trial diet comparison, though they lost about a quarter as much weight. Several authors are Eli Lilly employees and shareholders, and Lilly makes tirzepatide.[6]
Kilograms and proportions answer different questions
People lose more lean mass in absolute terms on a drug that removes more weight, even if the share stays flat. Compared with placebo, obesity-dose GLP-1 drugs lowered lean mass by 1.74 kg on average (95% CI -3.04 to -0.45) and by 5.44 kg with semaglutide, while lean mass as a proportion of total weight rose 1.81% (95% CI 1.1 to 2.52). Heterogeneity on the kilogram estimate was high (I² = 98%).[7] Both statements are true at once: less muscle-related tissue, and a body that is proportionally leaner. A network meta-analysis of 43 trials and 3,379 participants found the same split, with no significant difference in change in total lean tissue percentage but a significant decrease in lean mass for liraglutide 1.8 mg, semaglutide 1.0 mg and tirzepatide 15 mg.[9]
Size of loss is an obvious confounder. A broad 2026 review of 60 articles found GLP-1 drugs reduced lean or fat-free mass but rated certainty as low and said the changes “appeared largely related to weight loss.”[8] That fits the mechanism described in our article on the biology of lean mass loss. The old rule that a quarter of diet weight loss is fat-free mass has also been questioned: a critical review noted that lean losses with dieting tend to be small, raising doubts about study power and measurement reliability.[10] Small denominators matter here. In the Annals of Internal Medicine review, comparator groups lost a median of just 2.5% of their weight, so their shares rest on very little loss.[3]
Fat-free mass is not the same as muscle
DXA and bioimpedance estimate fat-free mass or lean soft tissue, which is not the same thing as skeletal muscle.[11] Losing fat tissue itself forces some fat-free loss, because an estimated 15% to 20% of adipose tissue mass is water and protein.[11] The Annals review tried to account for this by setting different benchmarks: about 25% for DXA or bioimpedance and about 15% for CT or MRI. Across 35 studies, a median of 28.3% of weight lost on incretins came from muscle-related indices, and 65% of results exceeded the benchmark.[3] In comparator groups that lost weight, 38% exceeded it, while the abstract’s conclusion says “nearly half,” a wording gap we can’t resolve from the abstract.[3]
The same review found that no study reported objective physical function.[3] That gap matters more than any percentage. A lower lean mass number does not by itself mean weaker or less mobile. Another review says reductions in lean mass “should not be interpreted as synonymous with sarcopenia,” while also saying the evidence can’t exclude clinically relevant loss in susceptible people.[4] Our article on GLP-1 use after 65 looks at that group.
Against bariatric surgery
Surgery removes more of everything. In a single-center retrospective cohort of 3,066 patients measured by bioimpedance, adjusted fat-free mass fell 10.6% at 12 months after surgery and 3.0% on semaglutide or tirzepatide, while fat mass fell 49.7% and 17.3%. The fat-free-to-fat-mass ratio improved in both groups and stayed higher after surgery.[12] It is an observational cohort, so it shows association, and GLP-1 patients were required to have at least two prescriptions or 5% weight loss.[12] In the randomized-trial review, the fat-free share of weight lost was numerically close: 33.3% with incretins and 34.2% with surgery.[2]
Exercise may lower the lean share
Both reviews show a lower lean share when exercise is added, though neither reports a test of exercise against drug choice. Diet alone accounted for 22.3% and diet with exercise 7.7% in one review, a descriptive comparison, and some exercise groups gained fat-free mass.[2] The other reported 26.2% for lifestyle and 17.5% for lifestyle plus resistance training.[1] Both figures come from lifestyle trials, not from people on a GLP-1, so they suggest what exercise might do rather than prove it on the drug. The practical steps sit in our muscle loss prevention protocol.
What to raise with a prescriber
- Whether your age or health makes lean mass loss more of a concern, since the data can’t rule out clinically relevant loss in susceptible people.[4]
- Whether a body composition scan is useful for you, and whether the same method can be repeated, because results vary by method.[3]
- How to add resistance training and adequate protein to treatment, which is what the authors of the lifestyle comparison recommend.[1]
- Whether a strength or function test would tell you more than a lean mass number, given how little function has been measured.[3]
Our reviews
Providers that prescribe GLP-1s online
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.0. Read our review of PlexusDxNationwide compounded GLP-1 with optional genetic-test personalizationFrom$69/momicrodose, 12-month plan ratecompounded
- Editorial score: 6.9. Read our review of DudeMedsMen seeking no-fee compounded or brand-name GLP-1 injectionsFrom$175/mo6-month plan ratecompounded
- Editorial score: 6.9. Read our review of TMatesNationwide compounded GLP-1 availabilityFrom$249/mocompounded
- Editorial score: 6.9. Read our review of YourEraFlat month-to-month pricing on compounded GLP-1s at every doseFrom$89/mocompounded
- Editorial score: 6.2. Read our review of WellorithmFlat-priced compounded semaglutide or tirzepatide injections in all 50 statesFrom$299/moafter intro offercompounded
Also for this topic
For the muscle side: strength-training apps
Workout apps and coaching for the exercise side of your plan. Each opens our full, independent review.
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026. PMID: 41877354.
- 2.Busk-Cirera L, Carlsen IØ, Madsen LB, et al. Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42324178.
- 3.Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med. 2026. PMID: 41996180.
- 4.Lopes Menezes ML, Güntzel Chiappa ME, Kloss RF, et al. Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework. Diabetes Obes Metab. 2026. PMID: 42608323.
- 5.Silver HJ, Olson D, Mayfield D, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023. PMID: 37188932.
- 6.Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
- 7.Laverde LP, Muñoz-Velandia OM, Alfonso D, et al. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). Int J Obes (Lond). 2026. PMID: 42321502.
- 8.Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs. 2026. PMID: 42730869.
- 9.Wachiraphansakul N, Vongchaiudomchoke T, Manosroi W, et al. Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026. PMID: 42209204.
- 10.Heymsfield SB, Gonzalez MC, Shen W, et al. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014. PMID: 24447775.
- 11.Tinsley GM, Heymsfield SB. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. J Endocr Soc. 2024. PMID: 39372917.
- 12.Wang Z, Wang L, Zhang X, et al. Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. JAMA Netw Open. 2026. PMID: 41511769.
Related research
Tirzepatide Body Composition: SURMOUNT-1 & SURPASS-3 Imaging
Tirzepatide imaging evidence: SURMOUNT-1 DXA cut visceral fat ~40% with ~74% of weight lost as fat; SURPASS-3 MRI slashed liver fat. (No real SURMOUNT-MORPH.)
13 min read
Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review
Bimagrumab is an investigational antibody that blocks ActRII to build muscle while cutting fat — the opposite of GLP-1 muscle loss. Phase 2 evidence: -20.5% fat, +3.6% lean, plus the BELIEVE bimagrumab + semaglutide trial.
9 min read
Time-Restricted Eating With Lifting: Fat Loss or Muscle Loss?
Short trials suggest time-restricted eating alongside resistance training may trim a little fat without clear muscle loss. Here is what new meta-analyses show, why calories and protein may explain much of it, and where the evidence stops.
8 min read
Sarcopenic Obesity and GLP-1 Drugs: Protecting Muscle While Losing Fat
Sarcopenic obesity — excess fat plus low muscle, at any age per the 2022 ESPEN/EASO consensus — collides with GLP-1 weight loss, where about a quarter to a third of weight lost can be lean mass. The evidence and the muscle-protective fix.
9 min read
Peptides to Preserve Muscle on GLP-1: What the Evidence Shows
No human RCT shows sermorelin, ipamorelin, CJC-1295, BPC-157, or tesamorelin preserves muscle during GLP-1 therapy. A review of each peptide best human data vs the resistance-training and protein evidence that works.
11 min read
Pemvidutide (Altimmune): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence
Pemvidutide is Altimmune's investigational GLP-1/glucagon dual agonist, not FDA-approved. The phase 2 MOMENTUM obesity topline (-15.6% at 48 weeks on 2.4 mg) and the phase 2b IMPACT MASH results, its body-composition signal, and how it compares to approved drugs.
9 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →From $179/mo
prepaid plan rate
Found
Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s
Read full review →From $239/mo
12-month plan rate
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $250/mo
starting dose